CytRx
was recently featured in a third article by Seeking Alpha contributor John
Mylant, who writes of the potential of the company’s flagship leading drug
candidate, aldoxorubicin, as an alternative to widely used chemotherapeutic
agent doxorubicin.
CytRx
Wednesday released positive phase 2b sarcoma data, triggering a 75 percent
rally in company shares. The trial results reveal the company was successful in
meeting its primary endpoint of progression-free survival (PFS), outshining PFS
rates achieved with doxorubicin.
To
read the full article visit http://seekingalpha.com/article/1895201
The
overall response rate was 25.4% for aldoxorubicin subjects versus 5.4% for
doxorubicin subjects. As assessed by blinded central lab review, 23.0% of
aldoxorubicin subjects had a partial response while 0.0% of doxorubicin
subjects exhibited any objective response.
As
determined by both the trial investigators and by blinded central radiology
review, subjects treated with aldoxorubicin demonstrated highly statistically
significant better clinical outcomes than those receiving standard doxorubicin
therapy for their soft tissue sarcomas.
Mylant
has covered CytRx’ progress in two other articles and says he continues to
educate the investment community about the company as a long-term investment.
His bullish take is supported by the recently completed clinical study, he
says.
“The
results continue to support my belief that CytRx Corp. is a good long-term
value investment and aldoxorubicin will be the company’s first huge revenue
generating drug. This is amazing news for long-term investors,” concludes
Mylant.
For
more information, visit www.cytrx.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
